First order?Save 20%
(888) 510-7196
Shop
Learn
Lab Testing
SunshineGPT
10-Second Reorder
Free shipping!Every order through 9/30/26Free shipping on all orders
Go back
Caring SunshineIngredients

Vanillin

Table of contents

Other Names

2-Methoxy-4-formylphenol3-Methoxy-4-hydroxybenzaldehyde4-Formyl-2-methoxyphenol4-Hydroxy-3-methoxybenzaldehyde4-Hydroxy-5-methoxybenzaldehyde4-Hydroxy-m-anisaldehydeBenzaldehyde, 4-hydroxy-3-methoxy-FEMA 3107Lioxinm-Anisaldehyde, 4-hydroxy-m-Methoxy-p-hydroxybenzaldehydeMethylprotocatechuic aldehydeNSC 15351p-Hydroxy-m-methoxybenzaldehydep-VanillinProtocatechualdehyde, methyl-VanilinVanilin (Turkish)VanilinaVanilina (Spanish/Portuguese)VanillaldehydeVanillic aldehydeVanillin (German)VanillinaVanillina (Italian)VanillineVanilline (French)ZimcoΒανιλίνη (Greek)

Synopsis

Vanillin

1. Identity: Chemical, Botanical, and Physical Characteristics

Chemical Identity

Vanillin is an organic compound with the molecular formula C₈H₈O₃. It is a phenolic aldehyde whose functional groups include an aldehyde, a hydroxyl group, and an ether (methoxy) group. Its systematic chemical name is 4-hydroxy-3-methoxybenzaldehyde, and it is the predominant compound in natural vanilla flavor — a complex mixture comprising over 200 compounds.

Vanillin (4-hydroxy-3-methoxybenzaldehyde) is the major organoleptic component of vanilla flavour. Ethylvanillin, a closely related compound also used by the food industry, has a stronger aromatic note and differs from vanillin by having an ethoxy group (−O−CH₂CH₃) instead of a methoxy group (−O−CH₃).

Botanical Sources

Vanillin is the main constituent of vanilla bean extract, obtained from the seed pods of various members belonging to the Orchidaceae family. Vanilla is the most popular flavor in the world and the second most valuable spice after saffron. The principal commercial species is Vanilla planifolia Andrews (also known as V. fragrans), which is native to tropical Mexico and Central America. Other vanilla-producing orchid species include Vanilla tahitensis and Vanilla pompona.

The production of vanilla bean is a lengthy process that is highly dependent on suitable soil and climatic conditions. Beans appear after 4–5 years of cultivation, and the aroma is developed in the fruit after a long process called "curing" that takes approximately 6 months. Vanillin levels in the pod peak 6 months after pollination, followed by a steady increase in the glucoside form.

In addition to extraction from the vanilla orchid, vanillin can be produced from different carbon sources, such as eugenol, isoeugenol, lignin, ferulic acid, sugars, and waste residues.

Forms and Preparations

There are three sources of vanillin: natural, chemical/synthetic, and biotechnological. Depending on the source and the synthesis procedure, vanillin is categorized as either a natural or an artificial flavour.

  • Natural vanillin: Extracted directly from cured Vanilla planifolia pods via solvent (ethanol/water) extraction. Less than 5% of worldwide vanillin production comes from natural vanilla.
  • Synthetic/chemical vanillin: Vanillin was first synthesized from eugenol found in oil of clove and afterward from lignin-containing sulfite liquor, a byproduct of wood pulp processing in paper manufacture. Today, most synthetic vanillin is synthesized in a two-step process from the petrochemical precursors guaiacol and glyoxylic acid.
  • Biotechnological (bio-based) vanillin: Bio-based vanillin, derived from sources like eugenol and ferulic acid, is gaining popularity, particularly eugenol-based bio-vanillin in the high-end food and beverage market for its robust aroma and safety, despite its limited production yield (less than 1 g/L).

The largest use of vanillin is as a flavoring, usually in sweet foods. The ice cream and chocolate industries together comprise 75% of the market for vanillin as a flavoring, with smaller amounts being used in confections and baked goods. Vanillin is also used in the fragrance industry, in perfumes, and to mask unpleasant odors or tastes in medicines, livestock fodder, and cleaning products.

2. Historical and Traditional Use

Pre-Columbian Mesoamerica

Vanilla beans, called tlilxochitl, were discovered and cultivated as a flavoring for beverages by native Mesoamerican peoples, most famously the Totonacs of modern-day Veracruz, Mexico. Since at least the early 15th century, the Aztecs used vanilla as a flavoring for chocolate in drinks called xocohotl. Early Americans utilized vanilla in their medicinal and culinary practices and introduced the Spanish conquerors to the sweet bean.

The Totonac people's mastery of vanilla cultivation laid the foundation for vanillin's cultural significance. Their intricate pollination techniques and reverence for the vanilla orchid ensured that the beans remained a coveted commodity.

Archaeological Evidence

Although it is generally accepted that vanilla was domesticated in Mesoamerica and subsequently spread to the Old World in the 16th century, in 2019, researchers published a paper stating that vanillin residue had been discovered inside jars within a tomb in Canaan dating to the 2nd millennium BCE, suggesting the possible cultivation of an unidentified, Old World-endemic Vanilla species in Canaan since the Middle Bronze Age. Traces of vanillin were also found in wine jars in Jerusalem, which were used by the Judahite elite before the city was destroyed in 586 BCE.

In three small juglets recovered archaeologically, analysis detected significant amounts of the principal components of natural vanilla, including vanillin, as well as lower concentrations of 4-hydroxybenzaldehyde and acetovanillone (compounds derivative of vanillin). These compounds are the earliest archaeological evidence for the exploitation of a vanilla-infused oil in the Old World and most probably worldwide.

European Historical Use

When, in around 1520, the Spanish arrived with the conquistador Cortez, legend states that they tasted a new drink composed of chocolate flavored with vanilla and decided to import this beverage to Spain. Vanilla then became very popular all around Europe. Throughout Europe, vanilla was used in desserts and taken orally for ailments from fevers to hysteria.

Although vanilla's rich history is steeped in ritualistic, sexual, and culinary uses, only recently has the sweet orchid come into its own as a scientifically efficacious commodity. Because of advances in chemistry and pharmacology, most of the earlier medicinal uses of vanilla have given way to functional uses of vanillin, vanilla's main constituent.

Isolation and Synthetic History

Vanillin was first isolated as a relatively pure substance in 1858 by Théodore Nicolas Gobley, who obtained it by evaporating a vanilla extract to dryness and recrystallizing the resulting solids from hot water. The initial breakthrough in chemical synthesis came from German chemists Ferdinand Tiemann and Wilhelm Haarmann, who synthesized vanillin from coniferin in 1874. This innovation paved the way for the production of vanillin from lignin, a byproduct of the paper industry, making the compound more affordable and available. Tiemann and Haarmann founded a company, Haarmann and Reimer (now part of Symrise), and started the first industrial production of vanillin using their process in Holzminden, Germany. In 1876, Karl Reimer synthesized vanillin from guaiacol.

Rhône-Poulenc, now Solvay, commercialized a pure petrochemical route in the 1970s.

3. Key Constituents and Active Compounds

Primary Constituent: Vanillin Itself

Natural vanilla extract is a mixture of several hundred different compounds in addition to vanillin. Vanillin is the single most abundant and characterizing component. Co-occurring compounds in natural vanilla include vanillic acid, vanillyl alcohol, p-hydroxybenzaldehyde, guaiacol, and various esters and lactones — none of which are present in isolated or synthetic vanillin.

Structural Features Relevant to Bioactivity

In vitro and in vivo studies demonstrate that the anti-inflammatory nature of vanillin and its derivatives is mainly due to its involvement in the control of the expression of various genes, which contribute to the reduced secretion of pro-inflammatory cytokines (IL-1β, IL-8, IL-6, TNF-α), the reduced activity of the COX-2 and inducible nitric oxide synthase (iNOS) enzymes with the subsequent reduction of produced NO and prostaglandins, and the increased secretion of anti-inflammatory cytokines (IL-4, IL-10, TGF-β).

Vanillin and apocynin can inhibit the enzymatic activity of phosphoinositide 3-kinase (PI3K), as revealed by an in vitro lipid kinase assay, suggesting that inhibition of PI3K activity is a mechanism underlying the inhibitory effect on cancer cell migration; the presence of an aldehyde or ketone group in the vanillin structure was identified as important for this inhibition.

Antioxidant Mechanism

Vanillin is reported to be a potent scavenger of reactive oxygen species (ROS), as observed in multiple antioxidant assays including ORAC (oxygen radical absorbance capacity), ABTS⁺, and oxidative haemolysis inhibition, where it operates by self-dimerization contributing to high reaction stoichiometry.

Anti-Inflammatory Mechanisms

Vanillin was found to inhibit nitric oxide production in lipopolysaccharide (LPS)-activated RAW264.7 macrophages. Moreover, suppression of inducible nitric oxide synthase (iNOS) is closely related to this anti-inflammatory activity; RT-PCR studies revealed that vanillin concentration-dependently reduced the induction of iNOS mRNA in LPS-activated macrophages.

To elucidate the underlying mechanism, vanillin was found to inhibit LPS-activated NF-κB/MAPK pathways in RAW macrophages.

Antimicrobial Mechanisms

Membrane damage and energy metabolism disruption are important mechanisms of vanillin's inhibitory effect on E. coli O157:H7. Vanillin is a plant-derived antimicrobial volatile substance with potential microbial control applications in the food industry.

Anticancer Mechanisms

Vanillin has been reported to exhibit anti-invasive and antimetastatic activities by suppressing the enzymatic activity of matrix metalloproteinase-9 (MMP-9). Vanillin suppresses MMP-9 transcription by inhibiting nuclear factor-κB (NF-κB) activity, and Western blot confirmed that vanillin inhibited NF-κB activity through the inhibition of IκB-α phosphorylation and degradation.

Vanillin binds strongly to the active site cavity of calcium/calmodulin-dependent protein kinase IV (CAMKIV) and is stabilized by a large number of non-covalent interactions. CAMKIV is a member of the Ser/Thr kinase family and is associated with different types of cancer and neurodegenerative diseases. Vanillin inhibits the proliferation of human hepatocyte carcinoma (HepG2) and neuroblastoma (SH-SY5Y) cells in a dose-dependent manner.

Anti-Sickling Mechanism

Vanillin reacts covalently with sickle hemoglobin (HbS) both in solution and in intact red blood cells. Hemoscan oxygen equilibrium curves show a dose-dependent left shift, particularly at low oxygen tensions. Rheologic evaluation of vanillin-reacted HbS erythrocytes shows a dose-dependent inhibition of deoxygenation-induced cell sickling. Ektacytometry also suggests that vanillin may have a direct inhibitory effect on HbS polymer formation.

X-ray crystallographic studies with deoxyhemoglobin (HbA)-vanillin demonstrate that vanillin binds near His 103α, Cys 104α, and Gln 131β in the central water cavity. A secondary binding site is located between His 116β and His 117β, a residue implicated as a polymer contact site. Oxygen equilibrium, ektacytometry, and X-ray studies indicate that vanillin may decrease HbS polymerization by a dual mechanism: allosteric modulation to a high-affinity HbS molecule and stereospecific inhibition of T-state HbS polymerization.

4. Scientific Evidence by Area of Use

4.1 Antioxidant Activity

Vanillin possesses various biological effects, such as antioxidant, anti-inflammatory, antibacterial, and anticancer properties. Evidence for antioxidant activity is largely derived from in vitro assay data (ORAC, ABTS, FRAP) and preclinical animal models. No large-scale, controlled human clinical trials have specifically evaluated vanillin as a standalone antioxidant dietary supplement. The available evidence is therefore considered preliminary and mechanistic.

One rodent study evaluated vanillin's antioxidant and hepatoprotective properties in carbon tetrachloride (CCl₄)-treated rats. Vanillin markedly attenuated the expression levels of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6, and prevented CCl₄-induced hepatic cell alteration and necrosis. This is a preclinical (animal) finding and cannot be directly extrapolated to humans.

4.2 Anti-Inflammatory Activity

Both in vitro and in vivo research suggests that vanillin's anti-inflammatory effects are mainly due to its control over gene expression. This control results in a reduction in the secretion of pro-inflammatory cytokines (IL-1β, IL-8, IL-6, and TNF-α), a decrease in the activity of iNOS and COX-2, which reduces the amount of NO and prostaglandins produced, and an increase in the secretion of anti-inflammatory cytokines (IL-4, IL-10, and TGF-β).

A 2021 study using primary human gingival fibroblasts (HGF) — a human cell model — examined vanillin's anti-inflammatory and regenerative potential. In IL-1β-primed cells, preincubation with vanillin reduced IL-6, IL-8, COX-2, and iNOS expression and NO release. Moreover, vanillin determined increased gene expression of nAChRα7, leading researchers to hypothesize a role of vanillin in the activation of the cholinergic anti-inflammatory pathway. The results of this study highlight the anti-inflammatory and tissue repair ability of vanillin in IL-1β-primed HGF, suggesting potential therapeutic interest as an inflammatory modulator molecule with novel application in periodontal regeneration and oral health. This is an in vitro human cell study, not a clinical trial.

A 2024 PMC study tested vanillin in a mouse colitis model induced by multidrug-resistant E. coli. Compared to the blank control group, the LPS-stimulated group exhibited significant increases in IL-6, TNF-α, and IL-1β levels (p < 0.005), while vanillin treatment at concentrations ranging from 0.05 to 0.4 mg/mL produced a notable reduction in these cytokines (6–47%), accompanied by a significant increase in IL-10 production (47–85%) (p < 0.01). This is preclinical (animal/cell) evidence and should be characterized accordingly.

4.3 Antimicrobial Activity

Due to the increasing application of antibiotics in healthcare and conventional agriculture, multidrug-resistant (MDR) bacterial pathogens are rising worldwide. Vanillin and vanillic acid represent biologically active ingredients in vanilla that have been known for their antimicrobial effects besides their role as flavoring agents.

Vanillin exhibited potent antibacterial activity against various strains of MDR E. coli, Salmonella, and Staphylococcus aureus, with a minimal inhibitory concentration (MIC) of 1.25–2.5 mg/mL and a minimum bactericidal concentration (MBC) of 5–10 mg/mL.

Vanillin can impede the growth of fungal pathogens. For instance, vanillin at 250 mg/L decreased the growth of Alternaria strains, suggesting its fungistatic behaviour.

In interactions with common antibiotics, more than 70% of drug-drug interactions were bacterial species-specific, whereas 20% were strain-specific. In the case of vanillin and common antibiotics, both synergistic and antagonistic antimicrobial effects were discovered. All antimicrobial evidence is currently at the in vitro and preclinical animal level; no human clinical trials of vanillin as an antimicrobial agent have been reported in the peer-reviewed literature.

4.4 Anticancer Activity

Because chronic inflammation, neurodegeneration, and cancer are interrelated concepts, the anti-inflammatory mechanisms of vanillin not only have neuroprotective effects but are also considered crucial to the fight against cancer cells. The anti-cancer activity of vanillin and its derivatives is demonstrated across various types of cancer in vitro and in vivo.

In hepatocellular carcinoma cells (HepG2), vanillin reduced TPA-induced MMP-9 gelatinolytic activity and suppressed cell invasion through the down-regulation of MMP-9 gene transcription. Vanillin significantly reduced the 6.6-fold invasive capacity of HepG2 cells at noncytotoxic concentrations in the Matrigel invasion assay. Moreover, vanillin significantly suppressed the TPA-induced enzymatic activity of MMP-9 and decreased the induced mRNA level of MMP-9.

Furthermore, vanillin treatment resulted in significant reduction in mitochondrial membrane depolarization and ROS production, which eventually leads to apoptosis in HepG2 and SH-SY5Y cancer cells.

So far, only a few clinical trials with vanilla have been conducted. Only one of these clinical trials was directed to assess the therapeutic potential of vanilla itself; others were aimed at studying the calming effect of vanilla/vanillin fragrance on distressed infants with neonatal hypoxia and temporary apnoea. Although few in number, these trials suggest it is time to work towards realizing the therapeutic potential of vanilla/vanillin. The anticancer evidence remains exclusively preclinical (cell culture and animal models).

4.5 Sickle Cell Disease

Vanillin, a food additive, has been evaluated as a potential agent to treat sickle cell anemia. Earlier studies indicated that vanillin had moderate antisickling activity when compared with other aldehydes. Because vanillin is a food additive on the GRAS (generally regarded as safe) list, and because it has little or no adverse effects at high dosages in animals, vanillin was identified as a candidate for further evaluation as an agent for the treatment of sickle cell disease.

Studies indicate that vanillin may exhibit two related mechanisms of action as a potential antisickling agent: it not only inhibits sickle polymerization formation but also shifts the hemoglobin-oxygen association curve to the left, with an increase in the solubility of hemoglobin S molecules. Both mechanisms could lead to the reduction of vaso-occlusion episodes.

Subsequent work focused on synthetic vanillin derivatives with superior pharmacokinetic properties. Novel pyridyl derivatives of vanillin (including SAJ-310) exhibited superior in vitro binding and pharmacokinetic properties compared to vanillin, which translated into significantly enhanced allosteric and antisickling properties. Crystal structure studies of liganded Hb in the R2 quaternary state in complex with SAJ-310 provided important insights into the allosteric and antisickling properties of this group of compounds. No human clinical trials of vanillin per se as an antisickling agent have been published; evidence remains at in vitro and preclinical stages.

4.6 Neuroprotective Effects

Experimental evidence in animals has shown that vanillin acts as a neuroprotective agent in Huntington's disease (HD) and global ischemia.

In a cell model of Parkinson's-relevant neurotoxicity, a study aimed to elucidate the underlying neuroprotective mechanism of vanillin in rotenone-induced neurotoxicity in SH-SY5Y cells. Cells were treated with vanillin at various concentrations (5–200 nM) prior to rotenone (100 nM) exposure. Toxicity of rotenone was accompanied by loss of mitochondrial membrane potential, increased ROS generation, release of cytochrome-c, and enhanced expressions of proapoptotic markers via upregulation of p38 and JNK-MAPK pathway proteins. Vanillin pretreatment attenuated these effects in this in vitro model.

In a spinal cord injury (SCI) rat model, motor dysfunction was significantly improved in the vanillin-treated group compared to SCI rats. This was accompanied by altered levels of oxidative stress, inflammatory cytokines, and expressions of mitochondrial proteins, which were ameliorated by vanillin treatment. Vanillin also significantly reduced the number of TUNEL-positive cells in spinal cord tissues and decreased the number of HIF-1α-positive cells. In the SCI rat model, vanillin exerted neuroprotective effects of reducing apoptosis and attenuating the expression of HIF-1α in spinal tissues. This is preclinical (animal) evidence.

4.7 Bone Health

A 2024 cell-culture study (Pharmaceutics) examined vanillin's effects on bone-forming processes. Vanillin treatment induced mineralization as a marker for mature osteoblasts after stimulating alkaline phosphatase (ALP) staining and activity. The bone-forming processes of vanillin are mainly mediated by the upregulation of the bone morphogenetic protein 2 (BMP2), phospho-Smad1/5/8, and runt-related transcription factor 2 (RUNX2) pathway during the differentiation of osteogenic cells. Moreover, vanillin promoted osteoblast-mediated bone-forming phenotypes by inducing migration and F-actin polymerization. This is in vitro evidence; no clinical trials have been conducted.

4.8 Cardioprotective Activity

Vanillin is recognized as a widely known antioxidative, anti-apoptotic, anti-inflammatory, neuroprotective, and anticancer compound. However, no data are currently available concerning vanillin-mediated cardioprotective features. A study was designed to assess the consequences of vanillin treatment on doxorubicin-induced cardiotoxicity, employing a multiparametric approach using H9c2 cardiomyocyte cells both as a single agent and in combination with doxorubicin. Evidence in this area is limited to preclinical cell models.

5. Body Systems and Health Areas Associated with Vanillin

  • Immune/inflammatory system: Modulation of cytokine expression (TNF-α, IL-1β, IL-6, IL-10), inhibition of NF-κB and MAPK pathways, and suppression of COX-2 and iNOS.
  • Hematological system (sickle cell): Covalent modification of hemoglobin S; allosteric shift toward high-oxygen-affinity state; inhibition of HbS polymerization.
  • Nervous system: Preclinical neuroprotection in Huntington's disease, global ischemia, and spinal cord injury models; protection of dopaminergic neurons in rotenone-induced neurotoxicity models.
  • Gastrointestinal system: Antibacterial effects against food-borne pathogens (E. coli, Salmonella, Staphylococcus aureus) and observed reduction in colitis severity in mouse models.
  • Oncology (preclinical): Antiproliferative, antimetastatic, and pro-apoptotic effects demonstrated in hepatocellular carcinoma, neuroblastoma, and melanoma cell lines.
  • Musculoskeletal system: Promotion of osteoblast differentiation and mineralization via BMP2/RUNX2 signaling (in vitro only).
  • Cardiovascular system: Preliminary cardioprotective effects against doxorubicin-induced toxicity in cardiomyocyte cell models.
  • Skin and cosmetics: Vanillin decreased the production of pro-inflammatory cytokines and reduced UV-B-induced phosphorylation of ATM, Chk2, p53, p38/MAPK, JNK, S6RP, and H2A.X. All these factors play a central role in skin renewal and repair; therefore, using vanillin or its derivatives as cosmeceutical ingredients could also provide therapeutic benefit in addition to providing fragrant and antioxidant effects.

6. Dosage Forms and Dosages Reported in Studies

Important note: The following dosages are those reported in cited research studies, which are predominantly preclinical (animal or cell-culture). No standardized therapeutic dosage for human supplemental use has been established for any of the health conditions discussed.

  • JECFA Acceptable Daily Intake (ADI): The acceptable daily intake (ADI) for vanillin, as established by the Joint FAO/WHO Expert Committee on Food Additives (JECFA), is up to 10 mg/kg body weight per day.
  • Antibacterial (in vitro): MIC of 1.25–2.5 mg/mL and MBC of 5–10 mg/mL against MDR E. coli, Salmonella, and Staphylococcus aureus.
  • Anti-inflammatory (in vitro): Concentrations of 0.05–0.4 mg/mL in LPS-stimulated RAW 264.7 cells produced a notable reduction in TNF-α, IL-1β, and IL-6 levels.
  • Neuroprotection (cell culture): Vanillin pretreatment at concentrations of 5–200 nM in SH-SY5Y neuroblastoma cells; 100 nM was used as the effective dose.
  • Vanillin semicarbazone derivative — anticancer (animal): The lethal dose of vanillin semicarbazone (VSC) was 120 mg/kg for intraperitoneal treatment in male Swiss albino mice. For anticancer activities, three doses — 5, 7.5, and 10 mg/kg (i.p.) — were selected in the Ehrlich ascites carcinoma model.
  • Skin irritation (human patch tests): In closed-patch tests on human skin, vanillin caused no primary irritation when tested at concentrations of 20% on 29 normal subjects, 2% on 30 normal subjects, and 0.4% on 35 subjects with dermatoses. Maximization tests conducted on groups of 25 volunteers at concentrations of 2% and 5% in petrolatum produced no sensitization reactions.
  • Food flavoring market: With a market demand for approximately 20,000 tons of vanillin annually and a natural supply of less than 2,000 tons, there is growing interest in alternative production methods.

7. Safety Considerations and Interactions

Regulatory Status

Vanillin has been approved as a food additive and is considered "generally recognized as safe" (GRAS) for certain uses in food. The FDA classifies vanillin as GRAS for use in food. The EFSA has evaluated vanillin and considers it safe for consumption within specified limits. It is approved as a food additive and widely used in the European Union. The WHO, through the Joint FAO/WHO Expert Committee on Food Additives (JECFA), confirms its safety when consumed within recommended limits, recognizing it as a safe flavoring agent in global food standards.

Cumulative exposure estimates for vanillin-related substances (2.4 and 6.2 mg/kg body weight per day for adults and children, respectively) are above the threshold of toxicological concern for structural class I, but below the ADI of 0–10 mg/kg bw per day for vanillin established by JECFA.

Dermal Safety

Vanillin was found not to be responsible for most cases of sensitivity to natural vanilla. Human patch test data at concentrations up to 20% showed no primary irritation or sensitization reactions.

Inhalation Route Caution

GRAS status for vanillin as a food additive does not in itself mean that the flavorings are safe when used via inhalation. The food additive approval or GRAS status of a substance only applies to specific intended uses in food and is not supported by studies that consider inhalation toxicity. The toxicity of flavor chemicals should be re-evaluated, particularly regarding inhalation.

Antibiotic Interactions

More than 70% of drug-drug interactions between vanillin and antibiotics were bacterial species-specific, whereas 20% were strain-specific. In the case of vanillin and common antibiotics, both synergistic and antagonistic antimicrobial effects were discovered. The clinical significance of these in vitro interactions in humans has not been established.

Limitations of Current Evidence

The increase in the number of reports on the cyto-, neuro-, nephro-, cardio-, and hepatoprotective potential of vanillin may enhance the chances of vanillin being considered for clinical trials in the future. Further research in functional products (drug release systems or adjuvants) must be conducted, along with the much-needed clinical trials, to actually shed light on their promising health-promoting properties.

The bioavailability and hydrophobicity of vanillin limit its bioactive efficiency and pharmacokinetics. Nanocarriers or nanoparticles can potentiate the bioactive profile of vanillin, and much current research focuses on improving delivery systems for potential pharmaceutical applications.

It has been demonstrated that vanillin can induce oxidative stress under certain conditions; however, evidence also suggests its beneficial effects, including antioxidant and anti-inflammatory properties. The dose, route of exposure, and cellular context appear to be critical determinants of whether vanillin exerts pro-oxidant or antioxidant effects.

References

Health Conditions

Health conditions that Vanillin may help support.

  • No conditions available.

Body Systems

Body systems that Vanillin may help support.

  • No body systems available.
Join our newsletter

Stay informed. Stay healthy.

Get expert supplement tips, exclusive discounts, and product recommendations delivered to your inbox